Form 4 for PTN PALATIN TECHNOLOGIES INC
Accepted 2022-06-24 00:00:00 ET · period of report 2022-06-22 · accession 0001654954-22-008784 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-06-24 | 2022-06-22 | PTN | WILLS STEPHEN T | CFO, COO, Executive VP | A - Grant | $0.00 | +605.9K | 9.11M | +7% | $0 |
| DM | 2022-06-24 | 2022-06-22 | PTN | WILLS STEPHEN T | CFO, COO, Executive VP | A - Grant | $0.00 | +798.6K | 587.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-22 | A | A | 36,028 | $0.00 | 9,319,999 | D | — | — | (F4) Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 22, 2021, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. |
| 2 | Common | Common Stock | 2022-06-22 | A | A | 127,414 | $0.00 | 9,283,971 | D | — | — | (F3) Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 16, 2020, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. |
| 3 | Common | Common Stock | 2022-06-22 | A | A | 47,457 | $0.00 | 9,156,557 | D | — | — | (F2) Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 24, 2019, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. |
| 4 | Common | Common Stock | 2022-06-22 | A | A | 395,000 | $0.00 | 9,109,100 | D | — | — | (F1) Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of 25% per year, starting on June 22, 2023. |
| 5 | Derivative | Stock Option (Right to Buy) | 2022-06-22 | A | A | 211,136 | $0.00 | 211,136 | D | $0.58 · 2022-06-22 to 2030-06-22 | 211,136 Common Stock | (F6) Stock options granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, upon payment of the exercise price, one share of common stock. The performance condition stock option grant, made June 16, 2020, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of stock option shares for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. |
| 6 | Derivative | Stock Option (Right to Buy) | 2022-06-22 | A | A | 587,500 | $0.00 | 587,500 | D | $0.29 · 2026-06-22 to 2032-06-22 | 587,500 Common Stock | (F5) The options vest at the rate of 25% per year, starting on June 22, 2023. |